Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDITNASDAQ:FTLFOTCMKTS:IGXTNASDAQ:RAPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDITEditas Medicine$1.87-0.3%$1.38$0.91▼$6.22$156.96M2.152.57 million shs715,979 shsFTLFFitLife Brands$14.94+3.9%$13.55$9.83▼$17.75$140.30M0.918,096 shs8,063 shsIGXTIntelGenx Technologies$0.17$0.17$0.09▼$0.22$29.17M2.47N/AN/ARAPTRAPT Therapeutics$0.93-4.6%$0.97$0.71▼$4.60$122.10M-0.041.28 million shs150,090 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDITEditas Medicine+13.33%+24.67%+18.35%+2.19%-64.85%FTLFFitLife Brands-0.42%+3.45%-0.28%-1.44%-6.74%IGXTIntelGenx Technologies0.00%0.00%0.00%0.00%0.00%RAPTRAPT Therapeutics-0.30%+9.56%+5.62%-10.74%-76.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEDITEditas Medicine4.3898 of 5 stars3.14.00.04.23.21.71.3FTLFFitLife Brands4.43 of 5 stars3.75.00.00.02.03.33.1IGXTIntelGenx Technologies0.2424 of 5 stars0.03.00.00.00.61.70.0RAPTRAPT Therapeutics3.8159 of 5 stars3.21.00.04.22.61.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDITEditas Medicine 2.29Hold$5.36187.59% UpsideFTLFFitLife Brands 3.33Buy$20.5037.22% UpsideIGXTIntelGenx Technologies 0.00N/AN/AN/ARAPTRAPT Therapeutics 2.33Hold$3.00223.28% UpsideCurrent Analyst Ratings BreakdownLatest IGXT, FTLF, RAPT, and EDIT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025RAPTRAPT TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$2.00 ➝ $1.005/22/2025RAPTRAPT TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$6.005/13/2025EDITEditas MedicineRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$8.00 ➝ $4.004/29/2025EDITEditas MedicineCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/28/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.004/28/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$3.003/17/2025FTLFFitLife BrandsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.003/10/2025RAPTRAPT TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDITEditas Medicine$35.84M4.36N/AN/A$4.27 per share0.44FTLFFitLife Brands$63.86M2.20$0.78 per share19.05$3.04 per share4.91IGXTIntelGenx Technologies$1.04M28.05N/AN/A($0.07) per share-2.39RAPTRAPT Therapeutics$1.53M80.24N/AN/A$4.27 per share0.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDITEditas Medicine-$153.22M-$3.04N/AN/AN/A-340.96%-80.13%-50.99%8/6/2025 (Estimated)FTLFFitLife Brands$5.30M$0.8417.6813.58N/A13.38%28.03%15.13%N/AIGXTIntelGenx Technologies-$9.93M-$0.06N/A∞N/AN/AN/AN/AN/ARAPTRAPT Therapeutics-$116.80M-$2.40N/AN/AN/AN/A-89.10%-76.13%8/14/2025 (Estimated)Latest IGXT, FTLF, RAPT, and EDIT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025FTLFFitLife Brands$0.24$0.20-$0.04$0.20N/AN/A5/12/2025Q1 2025EDITEditas Medicine-$0.51-$0.43+$0.08-$0.92$0.79 million$4.66 million5/8/2025Q1 2025RAPTRAPT Therapeutics-$0.31-$0.08+$0.23-$0.08N/AN/A3/27/2025Q4 2024FTLFFitLife Brands$0.22$0.21-$0.01N/AN/AN/A3/6/2025Q4 2024RAPTRAPT Therapeutics-$0.45-$1.14-$0.69-$1.14N/AN/A3/5/2025Q4 2024EDITEditas Medicine-$0.39-$0.55-$0.16-$0.55$37.17 million$30.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDITEditas MedicineN/AN/AN/AN/AN/AFTLFFitLife BrandsN/AN/AN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/ARAPTRAPT TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDITEditas MedicineN/A3.753.75FTLFFitLife Brands0.281.500.64IGXTIntelGenx TechnologiesN/AN/AN/ARAPTRAPT TherapeuticsN/A9.909.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDITEditas Medicine71.90%FTLFFitLife Brands2.32%IGXTIntelGenx TechnologiesN/ARAPTRAPT Therapeutics99.09%Insider OwnershipCompanyInsider OwnershipEDITEditas Medicine1.90%FTLFFitLife Brands61.30%IGXTIntelGenx Technologies42.05%RAPTRAPT Therapeutics2.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDITEditas Medicine23083.71 million80.98 millionOptionableFTLFFitLife Brands209.39 million3.56 millionNot OptionableIGXTIntelGenx Technologies38174.66 million101.21 millionNot OptionableRAPTRAPT Therapeutics80132.29 million32.65 millionOptionableIGXT, FTLF, RAPT, and EDIT HeadlinesRecent News About These CompaniesWhat is HC Wainwright's Forecast for RAPT Q2 Earnings?May 27 at 1:18 AM | marketbeat.com12 Health Care Stocks Moving In Friday's Intraday SessionMay 25, 2025 | benzinga.comRAPT Therapeutics (NASDAQ:RAPT) Upgraded to Strong-Buy at HC WainwrightMay 25, 2025 | americanbankingnews.comRAPT Therapeutics (NASDAQ:RAPT) Upgraded to "Hold" at Wall Street ZenMay 24, 2025 | marketbeat.comUBS Group Issues Pessimistic Forecast for RAPT Therapeutics (NASDAQ:RAPT) Stock PriceMay 24, 2025 | marketbeat.comRAPT Therapeutics (NASDAQ:RAPT) Earns Buy Rating from HC WainwrightMay 24, 2025 | marketbeat.com11,764,000 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Acquired by RTW Investments LPMay 18, 2025 | marketbeat.comRapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should KnowMay 16, 2025 | zacks.com13,135,260 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Purchased by Orbimed Advisors LLCMay 15, 2025 | marketbeat.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of "Hold" by AnalystsMay 11, 2025 | marketbeat.comDeep Track Capital LP Invests $9.50 Million in RAPT Therapeutics, Inc. (NASDAQ:RAPT)May 9, 2025 | marketbeat.comColumn Group LLC Lowers Stock Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT)May 9, 2025 | marketbeat.comRAPT Therapeutics Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comWhy RAPT Therapeutics, Inc.’s (RAPT) Stock Is Down 5.55%May 8, 2025 | aaii.comBVF Inc. IL Acquires New Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT)May 6, 2025 | marketbeat.comRAPT Therapeutics (RAPT) to Release Earnings on ThursdayMay 3, 2025 | marketbeat.comTCG Crossover Management LLC Buys Shares of 13,135,260 RAPT Therapeutics, Inc. (NASDAQ:RAPT)May 1, 2025 | marketbeat.com1,243,513 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Purchased by Nantahala Capital Management LLCApril 30, 2025 | marketbeat.comForesite Capital Management VI LLC Invests $19.75 Million in RAPT Therapeutics, Inc. (NASDAQ:RAPT)April 30, 2025 | marketbeat.comIs RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?April 18, 2025 | finance.yahoo.comRapt Therapeutics appoints Jessica Savage as VP, clinical developmentApril 17, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIGXT, FTLF, RAPT, and EDIT Company DescriptionsEditas Medicine NASDAQ:EDIT$1.86 -0.01 (-0.27%) As of 11:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.FitLife Brands NASDAQ:FTLF$14.94 +0.56 (+3.89%) As of 11:49 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.IntelGenx Technologies OTCMKTS:IGXT$0.17 0.00 (0.00%) As of 05/27/2025IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.RAPT Therapeutics NASDAQ:RAPT$0.93 -0.04 (-4.62%) As of 11:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? CrowdStrike Stock Slips: Analyst Downgrades Before Earnings AutoZone Stock to Cross $4400 This Year: This Is Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
